Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Meningococcal type W most notable infectious disease in 2017 The report ‘State of Infectious Diseases in the Netherlands in 2017’ published by RIVM today, provides an overview of the most important developments in infectious diseases in the Netherlands and a
Meningococcal disease serious, but still rare Meningococcal disease is a disease caused by a bacterium, the meningococcus. There are several types of this bacterium. In most cases, it does not make you ill.
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Interspecies website transferred from RIVM to Utrecht University The Interspecies website which helps researchers to reduce and refine the use of laboratory animals is transferred to the 3Rs database Programme of the 3Rs-Centre Utrecht Life Sciences (ULS) of Utr
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.